CN104873501A - Sulbactam sodium composition for treating infectious diseases - Google Patents
Sulbactam sodium composition for treating infectious diseases Download PDFInfo
- Publication number
- CN104873501A CN104873501A CN201510247893.4A CN201510247893A CN104873501A CN 104873501 A CN104873501 A CN 104873501A CN 201510247893 A CN201510247893 A CN 201510247893A CN 104873501 A CN104873501 A CN 104873501A
- Authority
- CN
- China
- Prior art keywords
- sulbactam sodium
- crystal
- sulbactam
- weight portion
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a sulbactam sodium composition for treating infectious diseases, and relates to the technical field of medicines. The sulbactam sodium composition is prepared from the following raw materials in parts by weight: 1 part of sulbactam sodium and 0.3-0.5 part of anhydrous sodium carbonate, preferably 1 part of sulbactam sodium and 0.35-0.45 part of anhydrous sodium carbonate, wherein the sulbactam sodium is crystal; an X-ray powder diffraction pattern measured by a Cu-Kalpha ray is as shown in a figure I; the particle size of the crystal of the sulbactam sodium is 70-80 microns; and the distribution width is 55-90 microns. The novel crystal form of the sulbactam sodium disclosed by the invention is different from the crystal form structure in the prior art; an experiment proves that the sulbactam sodium composition disclosed by the invention is difficult in moisture absorption, and stable in long-term storage; and the medication safety is greatly improved.
Description
Technical field
The invention belongs to medical art, relate to a kind of sulbactam sodium composition for the treatment of infectious disease.
Background technology
Sulbactam sodium Chinese another name: (2S, 5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid sodium-4,4-dioxide; (2S-CIS)-3,3-dimethyl-7-oxo-4-sulfo--1-azabicyclo [3,2,0] heptane-2-carboxylic acid 4,4-dioxide sodium salt; English name Sulbactam Sodium; Molecular formula: C8H10NNaO5S; Molecular weight: 255.22; Molecular structural formula as shown in Figure 2;
Sulbactam sodium is irreversible competitive beta-lactamase inhibitor, all inhibitory action is had to the beta-lactamase that Grain-positive and negative bacterium (except bacillus pyocyaneus) produce, make enzyme deactivation after there is irreversible reaction with enzyme, inhibitor can not make the activity of enzyme be restored after removing.Sulbactam sodium has very strong and irreversible inhibitory action to the beta-lactamase that S. aureus L-forms and most gram negative bacilli produce.2 μ g/ml concentration are very strong to the inhibitory action of Richmond-Syks II, III, IV and V type beta-lactamase, but to I type beta-lactamase without effect.Can there is cooperative phenomenon when share in penicillins and cephalosporins and sulbactam sodium, the MIC of S. aureus L-forms, hemophilus influenza, escherichia coli, bacteroides fragilis etc. to front two class antibiotics resistances is dropped within sensitive range.
CN200910169645.7 discloses a kind of process for purification of sulbactam sodium compound, and the method comprises the following steps: first the pH value of its aqueous solution by water-soluble for sulbactam sodium crude product, is adjusted to acidity by a., collects the solid of separating out in solution; B. the solid obtained by step a, with after the organic solvent dissolution mixed with it, obtains solution to be refined; C. solution to be refined is placed in macroporous adsorbent resin, eluent purification, collects eluent; D. the eluent pH value that regulating step c obtains is neutrality, collects the solid of separating out, obtains sulbactam sodium highly finished product.The sulbactam sodium compound highly finished product purity adopting the method to obtain reaches more than 99.8%, and yield is more than 90%.
The storage stability of sulbactam sodium of the prior art is poor, in illumination and moist environment, its related substance can significantly increase, and long term storage impurity content is higher, and safety in utilization is poor, in order to obtain a kind of sulbactam sodium compound of more excellent performance, special proposition the present invention.
Summary of the invention
The object of the present invention is to provide a kind of sulbactam sodium composition for the treatment of infectious disease.
In order to complete object of the present invention, the technical scheme of employing is:
Treat a sulbactam sodium composition for infectious disease, it is characterized in that, consisting of of described compositions: sulbactam sodium 1 weight portion, natrium carbonicum calcinatum 0.3-0.5 weight portion; Described sulbactam sodium is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
Preferably, consisting of of sulbactam sodium composition of the present invention: sulbactam sodium 1 weight portion, natrium carbonicum calcinatum 0.35-0.45 weight portion.
Preferably, consisting of of sulbactam sodium composition of the present invention: sulbactam sodium 1 weight portion, natrium carbonicum calcinatum 0.35 weight portion.
Preferably, the main granularity of the crystal of sulbactam sodium described in sulbactam sodium composition of the present invention is 50-100 μm, and the dispersion of distribution is 40-110 μm.
Preferably, the main granularity of the crystal of sulbactam sodium described in sulbactam sodium composition of the present invention is 60-90 μm, and the dispersion of distribution is 50-100 μm.
Preferably, the main granularity of the crystal of sulbactam sodium described in sulbactam sodium composition of the present invention is 70-80 μm, and the dispersion of distribution is 55-90 μm.
Preferably, the dosage form of sulbactam sodium composition of the present invention is injection, and the preparation method of described injection comprises the following steps:
(1) take sulbactam sodium crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
The preparation method of the sulbactam sodium crystal in the present composition comprises the following steps:
Prepare the sulbactam sodium crude product saturated aqueous solution of 20 DEG C, then the ethyl acetate of saturated solution volume 50%, the mixed solvent of carbon tetrachloride is added, the volume ratio of described ethyl acetate, the mixed solvent of carbon tetrachloride is 2:1, after stirring, cooling limit, limit is stirred, cooling rate is 7-9 DEG C/h, mixing speed is 80-100 rev/min, add the acetone that volume is mixed solvent volume 5 times simultaneously, stop after being cooled to 0 DEG C stirring, leave standstill growing the grain 1-2 hour, filter, after vacuum drying 4-6 hour, obtain sulbactam sodium crystal.
Below technical scheme of the present invention is made further explanation:
Different solution polarity, Crystal solubility, crystallization condition, comprise crystallization temperature, mixing speed etc. and have a great impact nucleus formation tool.In order to improve the stability of sulbactam sodium, first the applicant has carried out the crystallization processes research of sulbactam sodium, in the present invention, inventor is by experiment repeatedly, continuous change recrystallisation solvent, method for crystallising and crystallization condition, sulbactam sodium is first made saturated solution by final discovery, then under specific stirring, adds the mixed solvent of ethyl acetate, carbon tetrachloride with specific speed, coordinate the acetone of specified quantitative again, can obtain that crystal formation is even, the good sulbactam sodium crystal form of mobile performance.
The present invention is by the precise controlling to crystallization condition, and prepared a kind of novel crystal forms unlike the prior art, the X-ray powder diffraction pattern of this sulbactam sodium crystal unlike the prior art.Simultaneously due to the ins and outs of this crystal formation, the stability of sulbactam sodium compound of the present invention increases substantially, and utilizes composition injection prepared by sulbactam sodium compound of the present invention, not easily moisture absorption, and storage stability is good, and security performance is higher.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction of sulbactam sodium crystal prepared by the embodiment of the present invention 1;
Fig. 2 is sulbactam sodium molecular structural formula.
Detailed description of the invention
Below by specific embodiment, summary of the invention of the present invention is described in further detail, but does not therefore limit content of the present invention.
embodiment 1:the preparation of sulbactam sodium crystal
Prepare the sulbactam sodium crude product saturated aqueous solution of 20 DEG C, then the ethyl acetate of saturated solution volume 50%, the mixed solvent of carbon tetrachloride is added, the volume ratio of described ethyl acetate, the mixed solvent of carbon tetrachloride is 2:1, after stirring, cooling limit, limit is stirred, cooling rate is 7-9 DEG C/h, mixing speed is 80-100 rev/min, add the acetone that volume is mixed solvent volume 5 times simultaneously, stop after being cooled to 0 DEG C stirring, leave standstill growing the grain 1-2 hour, filter, after vacuum drying 4-6 hour, obtain sulbactam sodium crystal.
The X-ray powder diffraction pattern that the sulbactam sodium crystal prepared uses the measurement of Cu-K alpha ray to obtain as shown in Figure 1, measure through sem observation and particle size analyzer, the main granularity of this sulbactam sodium crystal is 70-80 μm, and the dispersion of distribution is 55-90 μm.Its purity of high-performance liquid chromatogram determination is 99.99%.
embodiment 2:the preparation method of sulbactam sodium composition, step is as follows:
Consist of: sulbactam sodium crystal 1 weight portion prepared by the present invention, natrium carbonicum calcinatum 0.3 weight portion.
Preparation method is:
(1) take sulbactam sodium crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 3:the preparation method of sulbactam sodium composition, step is as follows:
Consist of: sulbactam sodium crystal 1 weight portion prepared by the present invention, natrium carbonicum calcinatum 0.5 weight portion.
Preparation method is:
(1) take sulbactam sodium crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 4:the preparation method of sulbactam sodium composition, step is as follows:
Consist of: sulbactam sodium crystal 1 weight portion prepared by the present invention, natrium carbonicum calcinatum 0.35 weight portion.
Preparation method is:
(1) take sulbactam sodium crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 5:the preparation method of sulbactam sodium composition, step is as follows:
Consist of: sulbactam sodium crystal 1 weight portion prepared by the present invention, natrium carbonicum calcinatum 0.45 weight portion.
Preparation method is:
(1) take sulbactam sodium crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
test example 1:related substance is checked
This test example detects related substance in sulbactam sodium 3 batch sample prepared by embodiment 1, this test is carried out according to Chinese Pharmacopoeia 2010 editions second annex VIII P residual solvent algoscopy, annex XIX F medicine impurity analysis guideline, and it the results are shown in Table 1:
Table 1 related substance assay
test example 2:raw material stability test
This experiment is carried out according to the method in Pharmacopoeia of the People's Republic of China version in 2010 two annex XIX C medicine stability test guidelines.Embodiment 1 sample is placed respectively under high temperature (30 ± 2 DEG C) and high humidity (RH is 65% ± 5%) condition, respectively at 0 month, January, February, March, June samples detection respectively, to investigate its stability, the results are shown in Table 2:
Table 2 accelerated test result
Can find out that sulbactam sodium crystal provided by the invention has good stability by table 2 result, and still lower through accelerating 6 months rear impurity content, ensure that drug safety.
test example 3:hygroscopicity is investigated
This test example is respectively under the condition of humidity 80% and 90%, and each sample thief 1g is placed on electronic balance, and time recording weight, to detect moisture absorption degree, the results are shown in Table 3.
Table 3 hygroscopicity testing result
Sulbactam sodium 3 batch sample of sample 1-3 prepared by embodiment 1, sample 4 is commercially available HARBIN PHARMACEUTICAL GROUP CO., LTD. General Pharm. Factory product.Can be found out by result of the test, compared with prior art, sulbactam sodium crystal not easily moisture absorption prepared by the present invention, good stability.
test example 4:compositions long-time stability are investigated
The composition sample and the commercially available injection sulbactam sodium injectable powder that the inventive method are obtained embodiment 2,3,4,5 carry out long-time stability investigation, at 25 ± 2 DEG C, place 36 months, the results are shown in 4 under relative humidity 60% ± 10% condition.
Table 4 long-term stable experiment result
As can be seen from Table 4, the stability of embodiment of the present invention product is obviously better than commercially available injection sulbactam sodium injectable powder, sample every quality index after long-term 30 months of the embodiment of the present invention has no significant change, all meet quality criteria requirements, and commercially available product occurs that under long term test condition impurity increases and degradation significant change under content, therefore adopt the product quality of the injection sulbactam sodium of sulbactam sodium crystal preparation of the present invention more stable, substantially increase drug safety.
Claims (7)
1. treat a sulbactam sodium composition for infectious disease, it is characterized in that, consisting of of described compositions: sulbactam sodium 1 weight portion, natrium carbonicum calcinatum 0.3-0.5 weight portion; Described sulbactam sodium is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
2. sulbactam sodium composition according to claim 1, is characterized in that, consisting of of described compositions: sulbactam sodium 1 weight portion, natrium carbonicum calcinatum 0.35-0.45 weight portion.
3. sulbactam sodium composition according to claim 1, is characterized in that, consisting of of described compositions: sulbactam sodium 1 weight portion, natrium carbonicum calcinatum 0.35 weight portion.
4. the sulbactam sodium composition according to the arbitrary claim of claim 1-3, is characterized in that, the main granularity of crystal of described sulbactam sodium is 50-100 μm, and the dispersion of distribution is 40-110 μm.
5. sulbactam sodium composition according to claim 4, is characterized in that, the main granularity of crystal of described sulbactam sodium is 60-90 μm, and the dispersion of distribution is 50-100 μm.
6. sulbactam sodium composition according to claim 5, is characterized in that, the main granularity of crystal of described sulbactam sodium is 70-80 μm, and the dispersion of distribution is 55-90 μm.
7. the sulbactam sodium composition according to any one of claim 1-6, is characterized in that, the dosage form of described compositions is injection, and the preparation method of described injection comprises the following steps:
(1) take sulbactam sodium crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510247893.4A CN104873501A (en) | 2015-05-15 | 2015-05-15 | Sulbactam sodium composition for treating infectious diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510247893.4A CN104873501A (en) | 2015-05-15 | 2015-05-15 | Sulbactam sodium composition for treating infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104873501A true CN104873501A (en) | 2015-09-02 |
Family
ID=53941358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510247893.4A Pending CN104873501A (en) | 2015-05-15 | 2015-05-15 | Sulbactam sodium composition for treating infectious diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104873501A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105085543A (en) * | 2015-09-10 | 2015-11-25 | 青岛蓝盛洋医药生物科技有限责任公司 | Sulbactam sodium composition serving as antibacterial drug |
| CN106432277A (en) * | 2016-09-21 | 2017-02-22 | 陕西顿斯制药有限公司 | Cefoperazone sodium compound and sulbactam sodium compound prepared with strong-field coupling crystallization technology as well as prepared composition |
| CN109134498A (en) * | 2017-07-19 | 2019-01-04 | 梁怡 | 1/20 water sulbactam sodium compound of one kind and its pharmaceutical composition |
| CN109160919A (en) * | 2017-07-28 | 2019-01-08 | 海南美兰史克制药有限公司 | 1/10 water sulbactam sodium compound of one kind and its drug combination preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872057A (en) * | 2005-05-25 | 2006-12-06 | 刘力 | Soluble compound medicinal preparation of antibacterial drugs, and preparation method |
| CN101036654A (en) * | 2006-03-15 | 2007-09-19 | 广州白云山天心制药股份有限公司 | Stable cefoperazone sulbactam medicine compound preparation |
| CN101837126A (en) * | 2010-04-27 | 2010-09-22 | 四川方向药业有限责任公司 | Cephalosporin antibacterial combination and medicinal preparation thereof |
-
2015
- 2015-05-15 CN CN201510247893.4A patent/CN104873501A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872057A (en) * | 2005-05-25 | 2006-12-06 | 刘力 | Soluble compound medicinal preparation of antibacterial drugs, and preparation method |
| CN101036654A (en) * | 2006-03-15 | 2007-09-19 | 广州白云山天心制药股份有限公司 | Stable cefoperazone sulbactam medicine compound preparation |
| CN101837126A (en) * | 2010-04-27 | 2010-09-22 | 四川方向药业有限责任公司 | Cephalosporin antibacterial combination and medicinal preparation thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105085543A (en) * | 2015-09-10 | 2015-11-25 | 青岛蓝盛洋医药生物科技有限责任公司 | Sulbactam sodium composition serving as antibacterial drug |
| CN106432277A (en) * | 2016-09-21 | 2017-02-22 | 陕西顿斯制药有限公司 | Cefoperazone sodium compound and sulbactam sodium compound prepared with strong-field coupling crystallization technology as well as prepared composition |
| CN109134498A (en) * | 2017-07-19 | 2019-01-04 | 梁怡 | 1/20 water sulbactam sodium compound of one kind and its pharmaceutical composition |
| CN109160919A (en) * | 2017-07-28 | 2019-01-08 | 海南美兰史克制药有限公司 | 1/10 water sulbactam sodium compound of one kind and its drug combination preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105560194B (en) | Cefotaxime powder-injection of high-purity and preparation method thereof | |
| CN104873501A (en) | Sulbactam sodium composition for treating infectious diseases | |
| CN101606910A (en) | A kind of ceftizoxime sodium medicine injectable powder and preparation method thereof, and synthetic method of bulk drug ceftizoxime sodium | |
| CN104958318A (en) | Medicinal sulbactam sodium composition for treating infectious diseases | |
| CN104997773A (en) | Anti-infective drug sulbactam sodium composite | |
| CN103417512B (en) | A kind of Biomox and preparation method thereof | |
| CN104876946A (en) | Sulbactam compound for treating infectious diseases, and preparation method therefor | |
| CN104876947A (en) | Cefetamet pivoxil hydrochloride hydrate crystals and dispersible tablet thereof | |
| CN104644629A (en) | Ampicillin sodium sulbactam sodium preparation for injection and preparation method thereof | |
| CN103524532B (en) | Ceftizoxime sodium compound crystal form, and preparing method and pharmaceutical preparation thereof | |
| CN103113390B (en) | Sulbactam sodium compound and medical composition of sulbactam sodium compound and mezlocillin sodium | |
| CN105085549A (en) | Cefaclor compound, medicine composition of cefaclor compound and bromhexine hydrochloride, and preparation of cefaclor compound | |
| CN102643255A (en) | Andrographolide compound | |
| CN104788421A (en) | Erdosteine compound for treating respiratory tract inflammation and preparation method of erdosteine compound | |
| CN102274233B (en) | Medicinal composition of cefoperazone sodium and tazobactam sodium | |
| CN103145736A (en) | Medicine composite containing cefamandole nafate compound | |
| CN103127114B (en) | Medicinal composition including piperacillin sodium and sulbactam sodium | |
| AU2012389714B2 (en) | Cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing same and uses thereof | |
| CN103230400A (en) | Drug composition of cefoperazone sodium and tazobactam sodium and preparation method thereof | |
| CN104844624B (en) | A kind of cefoperazone sodium sulbactam sodium eutectic and composition and method of making the same | |
| CN105085543A (en) | Sulbactam sodium composition serving as antibacterial drug | |
| CN102836130A (en) | Tebipenem pivoxil granules | |
| CN103193795B (en) | Pharmaceutical composition of amoxicillin sodium and sulbactam sodium | |
| CN103304604B (en) | Clindamycin phosphate compound and preparation method and pharmaceutical composition thereof | |
| CN105622635A (en) | Ceftizoxime sodium novel crystal form capable of reducing anaphylactic reactions and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150902 |